ArticleScientific reports2025
Local consolidative therapy extends survival in metastatic NSCLC with oligoresidual disease following first-line immunotherapy, irrespective of PD-L1 expression.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Treatment of oligometastatic lung cancers: new data, new drivers, new approaches.BMJ oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The role of local consolidative therapy (LCT) in metastatic non-small cell lung cancer (mNSCLC) with oligoresidual disease (ORD) after first-line immunotherapy remains undefined. This study evaluated survival outcomes of LCT in this population. We retrospectively analyzed 127 mNSCLC patients lacking EGFR/ALK alterations who developed ORD (≤ 3 organs or ≤ 5 residual lesions) following first-line PD-1/PD-L1 inhibitor therapy at two centers (2019-2025). Patients received LCT (surgery/SABR/MWA/cryoablation/SABT, n = 57) or systemic therapy alone (non-LCT, n = 70). Progression-free survival (PFS) and overall survival (OS) were compared via Kaplan-Meier analysis; multivariate Cox regression identified prognostic factors. LCT significantly prolonged median PFS (14.0 vs. 7.0 months; HR = 0.171, 95% CI: 0.109-0.268; P < 0.001) and OS (27.3 vs. 15.8 months; HR = 0.049, 95% CI: 0.031-0.078; P < 0.001) versus non-LCT. Notably, survival benefits were independent of PD-L1 expression: PD-L1-high (≥ 50%) subgroup: mPFS 15.4 vs. 11.2 months (P = 0.004); mOS 32.8 vs. 22.0 months (P < 0.001). PD-L1-low (< 50%) subgroup: mPFS 14.0 vs. 7.0 months (P < 0.001); mOS 25.4 vs. 13.8 months (P < 0.001). Multivariate analysis confirmed LCT (HR ~ PFS ~ = 0.171, HR ~ OS ~ = 0.049; both P < 0.001) and high PD-L1 (HR ~ PFS ~ = 0.269, HR ~ OS ~ = 0.136; both P < 0.001) as independent protective factors. Grade 3-4 adverse events occurred in 8.8% of LCT patients (pneumothorax/radiation edema). LCT enhances survival in mNSCLC with ORD post-immunotherapy, irrespective of PD-L1 status. These findings support integrating LCT into standard care for immunotherapy-responsive ORD populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.